NASDAQ: LSBLakeshore Biopharma Co Ltd Stock
$1.38-0.12 (-8%)
Updated Apr 17, 2025
LSB Price
$1.38
Fair Value Price
N/A
Market Cap
$263.12M
52 Week Low
$1.31
52 Week High
$11.20
P/E
-0.06x
P/B
0.44x
P/S
1.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$672.27M
Earnings
-$238.36M
Gross Margin
80.6%
Operating Margin
-33.03%
Profit Margin
-35.5%
Debt to Equity
1.38
Operating Cash Flow
N/A
Beta
0.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LSB Overview
Summit Healthcare Acquisition Corporation is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. It targets the healthcare industry, specifically in the pharmaceuticals, medtech, and diagnostics sectors. The company was incorporated in 2020 and is headquartered in Hong Kong.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LSB's potential to beat the market
- LSB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LSB
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important LSB news, forecast changes, insider trades & much more!
LSB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LSB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LSB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LSB is good value based on its book value relative to its share price (0.44x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
LSB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LSB due diligence checks available for Premium users.
Valuation
LSB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-177.72x
Market
27.98x
LSB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
4.05x
LSB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LSB's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
LSB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$830.1M
Debt to equity
1.38
LSB's short-term assets ($852.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LSB's short-term assets ($852.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LSB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
LSB vs Biotech Stocks
Lakeshore Biopharma Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.